Wave Life Sciences Ltd. (WVE)
NASDAQ: WVE · Real-Time Price · USD
13.09
+0.50 (3.97%)
At close: Feb 18, 2026, 4:00 PM EST
13.10
+0.01 (0.08%)
After-hours: Feb 18, 2026, 5:14 PM EST
Wave Life Sciences Employees
As of December 31, 2024, Wave Life Sciences had 288 total employees, including 287 full-time and 1 part-time employees. The number of employees increased by 20 or 7.46% compared to the previous year.
Employees
288
Change (1Y)
20
Growth (1Y)
7.46%
Revenue / Employee
$379,271
Profits / Employee
-$423,424
Market Cap
2.40B
Employees Chart
Employees History
| Date | Employees | Change (1Y) | Growth (1Y) | Full-Time | Part-Time |
|---|---|---|---|---|---|
| Dec 31, 2024 | 288 | 20 | 7.46% | 287 | 1 |
| Dec 31, 2023 | 268 | 16 | 6.35% | 266 | 2 |
| Dec 31, 2022 | 252 | 14 | 5.88% | 250 | 2 |
| Dec 31, 2021 | 238 | 18 | 8.18% | 235 | 3 |
| Dec 31, 2020 | 220 | -81 | -26.91% | 217 | 3 |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro | - |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro | - |
| Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro | - |
| Dec 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro | - |
| Dec 31, 2015 | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro | - |
Related Stocks
| Company Name | Employees |
|---|---|
| Zai Lab | 1,869 |
| Arcus Biosciences | 627 |
| Adaptive Biotechnologies | 619 |
| Galapagos NV | 558 |
| Travere Therapeutics | 385 |
| Dyne Therapeutics | 240 |
| Immunome | 168 |
| Disc Medicine | 142 |
WVE News
- 16 days ago - Wave Life Sciences Reclaims Rare Disease Drug From GSK, Targets Faster FDA Path - Benzinga
- 16 days ago - Wave Life Sciences Announces Plans to Accelerate Regulatory Engagement with Full Control of WVE-006 for Alpha-1 Antitrypsin Deficiency - GlobeNewsWire
- 4 weeks ago - MoneyShow's Best Investment Ideas For 2026: Part 9 - Seeking Alpha
- 5 weeks ago - Wave Life Sciences Ltd. (WVE) Presents at 44th Annual J.P. - Seeking Alpha
- 5 weeks ago - Wave Life Sciences Highlights Strategic Priorities for 2026 at the 44th Annual J.P. Morgan Healthcare Conference: Accelerating Development of WVE-007 (INHBE siRNA) for Obesity and Rapidly Advancing RNA Editing Portfolio - GlobeNewsWire
- 6 weeks ago - Wave Life Sciences to Present at 44th Annual J.P. Morgan Healthcare Conference - GlobeNewsWire
- 2 months ago - Why Did Wave Life Sciences Surge 147%? - Forbes
- 2 months ago - Wave Life Sciences Prices Upsized $350 Million Public Offering of Ordinary Shares and Pre-Funded Warrants - GlobeNewsWire